119 related articles for article (PubMed ID: 16202916)
21. Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time.
Cankovic L; Steenwyk BL; McGiffin DC; Nielsen VG
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):725-6. PubMed ID: 18832918
[TBL] [Abstract][Full Text] [Related]
22. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
[TBL] [Abstract][Full Text] [Related]
23. Plasma nitrate/nitrite (NOx) is not a useful biomarker to predict inherent cardiopulmonary bypass inflammatory response.
Viaro F; Baldo CF; Capellini VK; Celotto AC; Bassetto S; Rodrigues AJ; Evora PR
J Card Surg; 2008; 23(4):336-8. PubMed ID: 18598323
[TBL] [Abstract][Full Text] [Related]
24. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass.
Guzzetta NA; Bajaj T; Fazlollah T; Szlam F; Wilson E; Kaiser A; Tosone SR; Miller BE
Anesth Analg; 2008 Feb; 106(2):419-25, table of contents. PubMed ID: 18227295
[TBL] [Abstract][Full Text] [Related]
25. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
Jiang L; Yu JF
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
[TBL] [Abstract][Full Text] [Related]
26. Imperfect 'swan'.
Maddali MM; Dsouza M; Nasser Al-Maskari S
J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):e32-4. PubMed ID: 23672869
[No Abstract] [Full Text] [Related]
27. The venous ACT after heparin--how much discard?
Chauhan S; Rao BH; Ghosh T; Sahu M; Kapoor M; Saxena N
J Cardiothorac Vasc Anesth; 1998 Dec; 12(6):721-2. PubMed ID: 9854678
[No Abstract] [Full Text] [Related]
28. Vascular effects of propofol during cardiopulmonary bypass.
Hynynen M; Heinonen J
Acta Anaesthesiol Scand; 1992 Aug; 36(6):600. PubMed ID: 1514351
[No Abstract] [Full Text] [Related]
29. Commentary on: The relationship between heparin level and activated clotting time in the adult cardiac surgery population.
Fitzgerald D
Perfusion; 2009 Mar; 24(2):97. PubMed ID: 19654151
[No Abstract] [Full Text] [Related]
30. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
31. Lower dose of heparin for cardiopulmonary bypass is not necessarily associated with lower drainage loss.
von Heymann C; Krimphove M; Spies C
Eur J Cardiothorac Surg; 2005 Apr; 27(4):727; author reply 728. PubMed ID: 15784394
[No Abstract] [Full Text] [Related]
32. Mitral valve repair and cardiac transplantation in a patient with factor XII deficiency.
Veronesi R; Maurelli M; Bianchi T; Toscani M; Via G; Villani MA; Pettinella S; Santambrogio LG; Fuardo M
J Cardiothorac Vasc Anesth; 2005 Jun; 19(3):419-20. PubMed ID: 16130082
[No Abstract] [Full Text] [Related]
33. Does hemodilution by the crystalloid priming solution derange the efficacy of anticoagulation during cardiopulmonary bypass?
Srivastava AR; Banerjee A; Misra BB; Minhas H; Virmani S
J Card Surg; 2008; 23(3):239-45. PubMed ID: 18435639
[TBL] [Abstract][Full Text] [Related]
34. Validation of viscoelastic coagulation tests during cardiopulmonary bypass: reply.
Ortmann E; Klein AA; Besser MW
J Thromb Haemost; 2015 Dec; 13(12):2282. PubMed ID: 26407643
[No Abstract] [Full Text] [Related]
35. Validation of viscoelastic coagulation tests during cardiopulmonary bypass: comment.
Solomon C; Fickenscher K; Ormonde L; Ranucci M
J Thromb Haemost; 2015 Dec; 13(12):2279-81. PubMed ID: 26332686
[No Abstract] [Full Text] [Related]
36. Lung perfusion during cardiac surgery with cardiopulmonary bypass: is it necessary?
Gabriel EA; Fagionato Locali R; Katsumi Matsuoka P; Santiago Almeida L; Guerreiro Silva I; Capelozzi VL; Salerno TA; Buffolo E
Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1089-95. PubMed ID: 18786945
[TBL] [Abstract][Full Text] [Related]
37. Anaesthesia for paediatric cardiac surgery at the Red Cross War Memorial Children's Hospital.
Cooke RD
S Afr Med J; 1984 Sep; 66(10):369-71. PubMed ID: 6484758
[TBL] [Abstract][Full Text] [Related]
38. Effect of heparin-bonded pulmonary artery catheters on the activated coagulation time.
McNulty SE; Maguire DP; Thomas RE
J Cardiothorac Vasc Anesth; 1998 Oct; 12(5):533-5. PubMed ID: 9801973
[TBL] [Abstract][Full Text] [Related]
39. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
[TBL] [Abstract][Full Text] [Related]
40. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
